Summary: The Centers for Medicare & Medicaid Services modified its stem cell transplantation coverage policy, formerly catalogued as NCD 110.8.1, with an effective date of May 15, 2026. Here's what billing teams need to know before claims start moving through adjudication.
CMS stem cell transplantation coverage policy has been a moving target for years, and this 2026 update continues that pattern. The policy governs Medicare reimbursement for allogeneic and autologous stem cell transplants across a range of hematologic and oncologic indications. This policy does not list specific codes in the version data available — billing teams should cross-reference their current CPT and HCPCS charge capture against the full NCD text at CMS.gov and confirm code applicability with their MAC before the May 15, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Stem Cell Transplantation (Formerly 110.8.1) |
| Policy Code | N/A (formerly NCD 110.8.1) |
| Change Type | Modified |
| Effective Date | 2026-05-15 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Transplant Surgery, Bone Marrow Transplant Programs, Hospital Revenue Cycle |
| Key Action | Audit your transplant claims against updated medical necessity criteria before May 15, 2026 |
CMS Stem Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2026
The CMS stem cell transplantation coverage policy has historically drawn a sharp line between covered indications and those CMS considers experimental or investigational. That line is the center of every claim denial your team will face in this space.
Under the pre-modification framework of NCD 110.8.1, CMS covered allogeneic hematopoietic stem cell transplantation (HSCT) for specific leukemias, myelodysplastic syndromes, and certain lymphomas when medical necessity criteria were met. Autologous transplants had a narrower covered footprint — multiple myeloma and certain lymphomas being the most established covered indications.
Medical necessity for stem cell transplantation under CMS billing guidelines has always required that the transplant be the treatment of choice for the specific diagnosis, not a fallback after other therapies fail arbitrarily. Documentation needs to show the patient meets the diagnostic criteria for the covered indication, has appropriate performance status, and that the transplant facility meets CMS requirements.
Because this policy version was modified in 2026, your team needs to pull the current NCD text directly from CMS.gov. A modification can mean anything from clarified documentation language to an expanded or contracted list of covered indications. Without the full text in hand, you're billing against a policy you haven't read. That's how you generate claim denials that take months to resolve.
Prior authorization is not required at the NCD level for Medicare fee-for-service — but that does not mean you skip pre-authorization entirely. Medicare Advantage plans contracting with CMS follow different rules. If your patient is on a Medicare Advantage plan, prior authorization requirements apply and vary by plan. Confirm coverage before the patient hits the OR.
The real issue with stem cell transplantation billing is that the clinical complexity and the policy complexity move in parallel. A single transplant encounter can generate professional claims, facility claims, acquisition cost claims for the stem cell product itself, and post-transplant monitoring claims — each with different coverage rules. Your billing team needs to know which layer they're responsible for.
CMS Stem Cell Transplantation Exclusions and Non-Covered Indications
CMS has historically excluded several transplant indications from coverage under the stem cell transplantation coverage policy. These exclusions are where your exposure sits.
Transplants for solid tumor malignancies — outside of very specific circumstances — have generally not been covered. CMS has treated high-dose chemotherapy with autologous stem cell rescue for breast cancer, ovarian cancer, and most other solid tumors as investigational. If your program is billing these cases to Medicare, that's a problem that predates this modification and won't improve after May 15, 2026.
Allogeneic transplants for indications not explicitly listed as covered face the same wall. CMS doesn't extend coverage by analogy — if the indication isn't in the covered list, it isn't covered, regardless of how strong the clinical rationale looks in the chart.
Medical necessity documentation that's vague about the specific diagnosis code fails here more than anywhere else. "Hematologic malignancy" isn't a covered indication. "Acute myeloid leukemia, de novo, without FLT3 mutation" is. Your physicians need to understand that the specificity of their diagnosis documentation directly controls whether your claim pays or denies.
Coverage Indications at a Glance
Because the policy data available does not include the full NCD text for this 2026 modification, the table below reflects the established CMS coverage framework for stem cell transplantation based on prior NCD 110.8.1 criteria. Confirm all indications against the current policy text before billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Allogeneic HSCT for acute leukemia (AML, ALL) | Covered | See current NCD text | Medical necessity documentation required; facility must meet CMS transplant requirements |
| Allogeneic HSCT for myelodysplastic syndromes | Covered | See current NCD text | Specific MDS subtypes covered; confirm diagnosis specificity |
| Allogeneic HSCT for chronic myelogenous leukemia | Covered | See current NCD text | Confirm current NCD language — TKI-era criteria may apply |
| Autologous HSCT for multiple myeloma | Covered | See current NCD text | Among the most established autologous indications |
| Autologous HSCT for Hodgkin lymphoma (relapsed/refractory) | Covered | See current NCD text | Prior therapy documentation required |
| Autologous HSCT for non-Hodgkin lymphoma | Covered | See current NCD text | Histology-specific; confirm subtype meets criteria |
| HSCT for solid tumor malignancies (breast, ovarian, etc.) | Not Covered | N/A | Considered investigational by CMS |
| Allogeneic HSCT for indications not in NCD covered list | Not Covered | N/A | No coverage-by-analogy under Medicare NCD framework |
| Tandem transplants for most indications | Not Covered / Investigational | N/A | Limited exceptions; confirm with MAC |
CMS Stem Cell Transplantation Billing Guidelines and Action Items 2026
This is where you stop reading and start doing. The effective date of May 15, 2026 is not far out. Here's what your billing team needs to do now.
| # | Action Item |
|---|---|
| 1 | Pull the full modified NCD text from CMS.gov immediately. The policy data available here does not include the complete modification language. You cannot update your workflows against a summary. Get the primary source document before anything else. |
| 2 | Identify every open or pending stem cell transplantation claim in your queue. Any claim for a service on or after May 15, 2026 adjudicates under the modified policy. Claims for services before that date should adjudicate under the prior version. Don't mix criteria across dates. |
| 3 | Audit your charge capture for transplant-related CPT and HCPCS codes. This policy does not list specific codes in the version data available — which means your coding team needs to map your existing charge master entries against the current NCD text themselves. Don't assume codes that paid before will pay the same way after the modification. |
| 4 | Review medical necessity documentation templates with your clinical team. Stem cell transplantation billing lives or dies on diagnosis specificity and documented clinical rationale. If your physicians are using generic templates, update them before May 15, 2026. Every indication should map to a specific ICD-10-CM code that CMS recognizes as covered. |
| 5 | Confirm prior authorization requirements for all Medicare Advantage patients. Medicare fee-for-service doesn't require prior auth at the NCD level, but every MA plan operates differently. Run a prior auth check on every scheduled transplant case regardless of plan type. A denied auth is easier to fix before the procedure than after. |
| 6 | Contact your Medicare Administrative Contractor if the modification creates ambiguity for your patient mix. MACs issue local coverage determinations and guidance letters that sit on top of NCDs. If the 2026 modification changes criteria in a way that doesn't clearly apply to cases you're already scheduling, your MAC is the right call before May 15, 2026 — not after a denial lands. |
| 7 | Loop in your compliance officer. Stem cell transplantation reimbursement involves high dollar claims, complex multi-payer situations, and frequent off-label clinical use. If you're not certain how the 2026 modification applies to your specific patient population and program structure, get your compliance officer in the room before the effective date. This is not a policy you work out through trial and error. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Stem Cell Transplantation Under the Modified CMS Policy
The policy data available for this CMS stem cell transplantation coverage policy modification does not include a specific code list. The version data provided to PayerPolicy does not enumerate CPT, HCPCS, or ICD-10 codes.
This is not unusual for CMS NCD modifications — the NCD text often references clinical criteria without attaching a definitive code list, leaving code mapping to the billing team and the MAC.
What to Do Instead of Relying on This Table
Pull the full NCD text from CMS.gov and cross-reference against your current charge master. Common code categories in scope for stem cell transplantation billing include transplant preparation, stem cell acquisition and processing, the transplant procedure itself, and post-transplant evaluation — but the specific codes that apply to your claims depend on your facility type, your role in the care episode, and the specific modification language.
Work with your coding team and, if needed, a billing consultant who specializes in oncology or transplant reimbursement. The stakes on these claims are too high for educated guesses.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.